2mg indications
namd-card
nAMD
Long-lasting VEGF-A suppression

Long-lasting VEGF-A suppression

Up to 2x longer than ranibizumab,,

Proactive extended dosing

Proactive extended dosing

By Week 96 in the ALTAIR study:

  • Up to 60% of patients reached an injection interval of ≥12 weeks,
  • Up to 46% of patients reached an injection interval of 16 weeks
Decreased injection frequency

Decreased injection frequency

Achieve sustained VA gains with as few as 3 injections in Year 2

EYLEA
®
2mg: YOUR CHOICE FOR PROACTIVE TREAT AND EXTEND UP TO Q16

Sustained VEGF supression with EYLEA® 2mg

Sustained VEGF supression with EYLEA® 2mg
  • Blue
    Mean duration of VEGF-A suppression with EYLEA® 2mg:67+/-14 days
  • Grey
    Mean duration of VEGF-A suppression with ranibizumab 34+/-5days
  • Blue and grey
    Definite VEGF suppression
  • gray-blue
    Uncertain suppression status
  • Blue to white
    Uncertain end of suppression

Long-lasting anti-VEGF up to 2X longer than ranibizumab (P<0.0001),

VA GAINS MAINTAINED AT YEAR 2 WITH PROACTIVE EXTENDED DOSING

VA GAINS MAINTAINED AT YEAR 2 WITH PROACTIVE EXTENDED DOSING

Q12 and beyond: VA gains observed in Year 1 and Year 2 of ALTAIR,

2-WEEK EXTENSION (n=124 EYES)

2-WEEK EXTENSION (n=124 EYES)

4-WEEK EXTENSION (n=123 EYES)

4-WEEK EXTENSION (n=123 EYES)

Mean number of injections at 96 weeks for both groups: 10.4 injections

ACHIEVE UNSURPASSED AND SUSTAINED VA GAINS WITH EYLEA
®
2mg

Treat and extend patients up to Q16,,

4-WEEK EXTENSION

4-WEEK EXTENSION
4-WEEK EXTENSION

Proportion of patients achieving ≥12-week dosing at 96 weeks

Proportion of patients achieving 16-week dosing at 96 weeks

2-WEEK EXTENSION

2-WEEK EXTENSION
2-WEEK EXTENSION

Proportion of patients achieving ≥12-week dosing at 96 weeks

Proportion of patients achieving 16-week dosing at 96 weeks

Achieve sustained VA gains with as few as 3 injections in Year 2 when proactive T&E is used with EYLEA® 2mg,

DOSING

Pro-active dosing options across indications

Read More
DOSING

MOA

Unique multi-targeted trap mechanism

Read More
MOA
    • 1
      Muether PS, Hermann MM, Dröge K, Kirchhof B, Fauser S. Long-term stability of vascular endothelial growth factor suppression time under ranibizumab treatment in age-related macular degeneration. Am J Ophthalmol. 2013;156:989-993.
    • 2
      Fauser S, Muether PS. Clinical correlation to differences in ranibizumab and aflibercept vascular endothelial growth factor suppression times. Br J Ophthalmol. 2016;100:1494-1498.
    • 3
      Fauser S, Schwabecker V, Muether PS. Suppression of intraocular vascular endothelial growth factor during aflibercept treatment of age-related macular degeneration. Am J Ophthalmol. 2014;158:532-536.
    • 4
      EYLEA® 2mg updated SPC as approved by the Israeli MoH.
    • 5
      Ohji M, Takahashi K, Okada AA, Kobayashi M, Matsuda Y, Terano Y; for ALTAIR Investigators. Efficacy and safety of intravitreal aflibercept treat-and-extend regimens in exudative age-related macular degeneration: 52- and 96-week findings from ALTAIR: a randomized controlled trial [published online ahead of print February 3, 2020]. Adv Ther. doi: 10.1007/s12325-020-01236-x.
    • 6
      Richard G, Monés J, Wolf S,
      et al
      . Scheduled versus pro re nata dosing in the VIEW trials. Ophthalmology. 2015;122:2497-2503.
    • 7
      Papadopoulos N, Martin J, Ruan Q,
      et al
      . Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap,ranibizumab and bevacizumab. Angiogenesis. 2012;15;171-185.